Brimonidine
- Generic Name
- Brimonidine
- Brand Names
- Alphagan, Combigan, Lumify, Mirvaso, Onreltea, Qoliana, Simbrinza
- Drug Type
- Small Molecule
- Chemical Formula
- C11H10BrN5
- CAS Number
- 59803-98-4
- Unique Ingredient Identifier
- E6GNX3HHTE
- Background
Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors tha...
- Indication
Opthalmic
Indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension as monotherapy or combination product with brinzolamide.
Topical
Indicated for the treatment of persistent (non-transient) facial erythema of rosacea in adults 18 years of age or older.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Facial erythema
- Associated Therapies
- -
Dry Eye Disease Study With Brimonidine
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 84
- Registration Number
- NCT03418727
- Locations
- 🇺🇸
Brenart Eye Clinic, Yorkville, Illinois, United States
🇺🇸Chicago Cornea Consultants, Hoffman Estates, Illinois, United States
🇺🇸The Eye Institute of Utah, Salt Lake City, Utah, United States
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Wills Eye
- Target Recruit Count
- 35
- Registration Number
- NCT03323164
- Locations
- 🇺🇸
Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States
The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 2
- Registration Number
- NCT03173365
- Locations
- 🇩🇪
Universitätsklinikum Düsseldorf, Klinik für Dermatologie, Düsseldorf, Germany
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 5
- Registration Number
- NCT03139708
- Locations
- 🇺🇸
Wake Forest Baptist Health Eye Center, Winston-Salem, North Carolina, United States
A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Galderma Brasil Ltda.
- Target Recruit Count
- 101
- Registration Number
- NCT02856919
- Locations
- 🇧🇷
Fundação do ABC, São Paulo, SP, Brazil
🇧🇷Centro Brasileiro de Estudos em Dermatologia, Porto Alegre - RS, RS, Brazil
🇧🇷Instituto de Dermatologia e Estética do Brasil Ltda, Rio de Janeiro, RJ, Brazil
Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Merete Haedersdal
- Target Recruit Count
- 19
- Registration Number
- NCT02761174
- Locations
- 🇩🇰
Bispebjerg Hospital, Copenhagen NV, Denmark
Brimonidine Tartrate for the Treatment of Injection Related Erythema
- Conditions
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Biogen
- Registration Number
- NCT02568111
Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 462
- Registration Number
- NCT02289352
- Locations
- 🇺🇸
Investigator site 2, Hot Springs, Arkansas, United States
🇺🇸Investigator site 15, Henderson, Nevada, United States
🇺🇸Investigator site 4, Nashville, Tennessee, United States
Mirvaso in Use Study
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 205
- Registration Number
- NCT02249065
- Locations
- 🇺🇸
Redwood Dermatology Research, Santa Rosa, California, United States
🇺🇸Manhattan Dermatology and Cosmetic Surgery, New York, New York, United States
🇺🇸DermDox Centers for Dermatology, Hazleton, Pennsylvania, United States
Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection
- Conditions
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Mashhad University of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT02140450
- Locations
- 🇮🇷
Retina Research Center, Khatam eye Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.